퀀타매트릭스
Financials
Valuation Metrics
퀀타매트릭스's Market Cap is ₩448B. At end of 2025 it was ₩964B. Ranked #1837 of 2,421 in KR market (top 76%), #1130 of 1,640 on KOSDAQ (top 69%), #193 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 44.80B KRW | KR#1,837/2,421 Sec#193/231 |
| Revenue | 3.15B KRW | KR#2,368/2,421 Sec#205/231 |
| Net Income | -17.85B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 43.22B KRW | KR#2,263/2,421 Sec#207/231 |
| Net Assets | 32.10B KRW | KR#2,153/2,421 Sec#191/231 |
| Employees | 91 | KR#1,713/2,421 Sec#135/231 |
| Value | ||
| P/B | 1.40x | KR#1,727/2,421 Sec#120/231 |
| P/S | 14.24x | KR#2,310/2,421 Sec#172/231 |
| FCF Yield | -34.84% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -55.60% | KR#2,293/2,421 Sec#200/231 |
| ROA | -41.29% | KR#2,351/2,421 Sec#212/231 |
| Op. Margin | -526.81% | KR#2,368/2,421 Sec#206/231 |
| Revenue Growth | 4.26% | KR#1,242/2,421 Sec#123/231 |
| Financial Health | ||
| Debt Ratio | 34.65% | KR#683/2,421 Sec#82/231 |
| Total Debt | 6.99B KRW | KR#1,727/2,421 Sec#161/231 |
| FCF | -15.61B KRW | KR#1,832/2,421 Sec#170/231 |
| Cash | 4.56B KRW | KR#2,031/2,421 Sec#188/231 |
| Current Ratio | 3.91x | KR#401/2,421 Sec#62/231 |
| Performance | ||
| 1Y Return | -52.91% | KR#2,108/2,421 Sec#195/231 |
| 1M Return | -9.18% | KR#2,058/2,421 Sec#172/231 |
| From 52W High | -60.69% | KR#1,883/2,421 Sec#147/231 |
| 1Y MDD | -61.62% | KR#1,572/2,421 Sec#127/231 |
| Trading | ||
| Volume | 44,678 shares | KR#1,182/2,421 Sec#117/231 |
| Trading Value | 99.1M KRW | KR#1,563/2,421 Sec#155/231 |
| Foreign Own. | 18.26% | KR#256/2,421 Sec#14/231 |
| Per Share | ||
| EPS | -886 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,594 KRW | KR#2,169/2,421 Sec#184/231 |
Company Info
Established in 2010 and listed on KOSDAQ in 2020, this company specializes in in vitro diagnostic medical devices. It develops microbial diagnostic technology-based testing systems (dRAST, QDST), molecular immunology platforms (QMAP), and automation equipment (QMIA), which are sold to advanced general hospitals both domestically and internationally. The company is also developing the uCIA system and pursuing the commercialization of the QPLEX Alz plus Assay kit for early diagnosis of Alzheimer's disease. Quantamatrix, established in 2010, is headquartered in Seoul Metropolitan City, Geumcheon-gu.